Noriko Koizumi
Directeur/Bestuurslid bij SEED CO.,LTD.
Profiel
Noriko Koizumi is an Independent Outside Director at Seed Co., Ltd., a Professor at Doshisha University, the Chief Scientific Officer at ActualEyes, Inc., and a Professor at Graduate School of Medicine Kyoto University.
She received her undergraduate and doctorate degrees from Kyoto Prefectural University of Medicine.
Actieve functies van Noriko Koizumi
| Bedrijven | Functie | Begin |
|---|---|---|
| SEED CO.,LTD. | Directeur/Bestuurslid | 24-06-2022 |
| Doshisha University | Corporate Officer/Principal | 01-04-2010 |
| Graduate School of Medicine Kyoto University | Corporate Officer/Principal | 01-04-2015 |
ActualEyes, Inc.
 ActualEyes, Inc. Packaged SoftwareTechnology Services ActualEyes, Inc. is a Japanese company that conducts research and development of products such as regenerative medicine for corneal endothelial disease. The company is based in Kyotanabe, Japan. The company's mission is to deliver the desired light to patients suffering from visual impairment and to ensure and promptly implement a new treatment society. The company was founded in 2018. The CEO is Iku Sugioka. | Hoofd Techniek/Wetenschap/O&O | 01-05-2018 |
Opleiding van Noriko Koizumi
| Kyoto Prefectural University of Medicine | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SEED CO.,LTD. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
ActualEyes, Inc.
ActualEyes, Inc. Packaged SoftwareTechnology Services ActualEyes, Inc. is a Japanese company that conducts research and development of products such as regenerative medicine for corneal endothelial disease. The company is based in Kyotanabe, Japan. The company's mission is to deliver the desired light to patients suffering from visual impairment and to ensure and promptly implement a new treatment society. The company was founded in 2018. The CEO is Iku Sugioka. | Technology Services |
